Filing Details
- Accession Number:
- 0001209191-22-024129
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-04-12 15:59:51
- Reporting Period:
- 2022-04-04
- Accepted Time:
- 2022-04-12 15:59:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
822370 | Emmaus Life Sciences Inc. | EMMA | Pharmaceutical Preparations (2834) | 870419387 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1517775 | C Willis Lee | 21250 Hawthorne Blvd. Suite 800 Torrance CA 90503 | Director & Coo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $0.001 Par Value | Acquisiton | 2022-04-04 | 3,200 | $0.98 | 238,194 | No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
Common Stock, $0.001 Par Value | Acquisiton | 2022-04-06 | 1,400 | $0.95 | 239,594 | No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
Common Stock, $0.001 Par Value | Acquisiton | 2022-04-08 | 1,600 | $0.76 | 241,194 | No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
Common Stock, $0.001 Par Value | Acquisiton | 2022-04-11 | 8,900 | $0.88 | 278,774 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
No | 4 | P | Indirect | By Fidelity Traditional IRA FBO Willis C. Lee |
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, $0.001 Par Value | 1,900 | Indirect | By Fidelity Roth IRA FBO Willis C. Lee |
Footnotes
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.75 to $0.78, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.89, inclusive.